These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9604997)

  • 1. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma.
    Lin WY; Yen TC; Cheng KY; Wang SJ
    Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
    Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
    Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Contribution of serum Cyfra 21-1 in nasopharyngeal carcinoma in Tunisia].
    Jmal A; Boussen H; Abdennebi M; Gara S; Harzallah L; Gritli S; Ladgham A; Guemira F; Ghanem A
    Bull Cancer; 2004 Apr; 91(4):369-72. PubMed ID: 15242321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
    Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
    Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue polypeptide specific antigen (TPS) as a tumor marker in nasopharyngeal carcinoma.
    Sun SS; Hsieh JF; Tsai SC; Ho YJ; Kao CH
    Anticancer Res; 2000; 20(6C):4661-3. PubMed ID: 11205197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.
    Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G
    Lung; 2001; 179(1):57-65. PubMed ID: 11479694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma].
    Ychou M; Khemissa-Akouz F; Kramar A; Senesse P; Grenier J
    Bull Cancer; 2001 Oct; 88(10):1023-7. PubMed ID: 11713038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
    Pavićević R; Milicić J; Bubanović G; Supe S
    Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-2-microglobulin (beta 2M) as a tumor marker in nasopharyngeal carcinoma.
    Lee JK; Tsai SC; Hsieh JF; Ho YJ; Sun SS; Kao CH
    Anticancer Res; 2000; 20(6C):4765-8. PubMed ID: 11205215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
    Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
    Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
    Ebert W; Muley T
    Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma.
    Lee JK; Hsieh JF; Tsai SC; Ho YJ; Sun SS; Kao CH
    Ann Otol Rhinol Laryngol; 2001 Aug; 110(8):775-8. PubMed ID: 11510737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
    Tsai SC; Kao CH; Wang SJ
    Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
    Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D
    J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
    Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
    Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer.
    Brockmann JG; St Nottberg H; Glodny B; Sprakel B; Senninger N
    Anticancer Res; 2000; 20(6D):4899-904. PubMed ID: 11332443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection.
    Yeh JJ; Liu FY; Hsu WH; Wang JJ; Ho ST; Kao A
    Lung; 2002; 180(5):273-9. PubMed ID: 12489021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.